A new report from a Working Group convened by the International Agency for Research on Cancer (IARC), the specialized cancer agency of the World Health Organization, and the United States National Cancer Institute(NCI) shows how the evaluation and licensing of prophylactic human papillomavirus (HPV) vaccines could be significantly accelerated. Experts with wide-ranging expertise in HPV vaccines reviewed the scientific evidence to determine under what circumstances vaccine efficacy can be established at an earlier stage of the infection, rather than the clinical onset of disease in the cervix. The experts also looked at whether immunobridging trials could be sufficient for licensure under specific circumstances. Read more here.
Read the full report, Primary end-points for prophylactic HPV vaccine trials, here.
No comments:
Post a Comment